Results 31 to 40 of about 132,650 (237)

Pharmacologic Properties of Proton Pump Inhibitors [PDF]

open access: yes, 2003
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90231/1/phco.23.13.74S.31929 ...
Welage, Lynda S.
core   +1 more source

Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients [PDF]

open access: yes, 2016
Purpose: Methotrexate administration is associated with frequent adverse neurological events during treatment for childhood acute lymphoblastic leukemia.
Baird, Susan F.   +5 more
core   +2 more sources

Proton pump inhibitor-induced Sweet’s syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer

open access: yesDermatology Practical & Conceptual, 2015
Background: Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug.
Philip R. Cohen
doaj   +1 more source

The choice of proton pump inhibitor from the standpoint of efficacy and safety in a particular patient

open access: yesЛечащий Врач, 2021
Proton pump inhibitors are a diverse class of drugs with unique acid suppression properties. The aim of the work was to present the therapeutic benefits of rabeprazole and pantoprazole in clinical practice.
E. A. Lyalukova   +3 more
doaj   +1 more source

Proton pump inhibitors overuse - consequences among patients

open access: yesJournal of Education, Health and Sport, 2019
Introduction Omeprazole was first proton pump inhibitor (PPI) approved for use by patients. Thirty years have passed since then. Due to their effectiveness, low price and safety proton pump inhibitors have become one of the most frequently prescribed ...
Patrycja Kmiotek   +2 more
doaj   +3 more sources

When proton pump inhibitors are compared, are there specific cases in which a certain proton pump inhibitors should be particularly preferred?

open access: yesThe Turkish Journal of Gastroenterology, 2017
Currently, proton pump inhibitors (PPIs) are widely used either over the counter or on prescription drugs. PPI’s are frequently used with other drugs when elderly and chronic desease burden population is taken to consideration.
Altay Çelebi, Hasan Yılmaz
doaj   +1 more source

Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study [PDF]

open access: yes, 2006
OBJECTIVE: In recent years, studies investigated to what extend recommendations for co-prescribing gastroprotective agents in prevention of NSAID-induced gastrointestinal complications are followed in clinical practice.
Bilušić, Marinko   +6 more
core   +1 more source

Refractory gastroesophageal reflux disease

open access: yesArquivos de Gastroenterologia, 2012
CONTEXT: Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications.
Joaquim Prado P. Moraes-Filho
doaj   +1 more source

Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events

open access: yesBMC Medicine, 2022
Background Approximately half of all women suffer from heartburn at some stage during pregnancy. The most effective treatment is proton pump inhibitors, but the safety of use during pregnancy cannot be guaranteed. This study aimed to elucidate the effect
Esmee M. Breddels   +6 more
doaj   +1 more source

Proton Pump Inhibitors Therapy in Children with Gastroesophageal Reflux [PDF]

open access: yes, 2013
Proton pump inhibitors (PPI) has been widely used by clinicians to treat diseases that require suppression of gastric acid. PPI work by inhibiting the proton pump in gastric parietal cells.In adult patients, PPI hasbeen widely studied and showed ...
Hegar, B. (Badriul), Reynaldo, A. (Aldo)
core  

Home - About - Disclaimer - Privacy